TPMPA

TPMPA, a hybrid of isoguvacine and 3-APMPA, is the first selective antagonist for a GABAC receptor (KB = 2.1 μM), but not to interact with GABAA (KB = 320 μM) or GABAB receptors (EC50 = 500 μM) . TPMPA has the potential for the research of suppressing orientation selectivity in ganglion cells[1][2][3].

Product Specifications

CAS Number

182485-36-5

UNSPSC

12352005

Hazard Statement

H315, H319, H320

Target

GABA Receptor

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel; Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/tpmpa.html

Purity

98.1

Solubility

H2O : 25 mg/mL (ultrasonic)

Smiles

O=P(C1=CCNCC1)(C)O

Molecular Formula

C6H12NO2P

Molecular Weight

161.14

Precautions

H315, H319, H320

References & Citations

[1]Martínez-Torres A, et al. GABArho 1/GABAAalpha 1 receptor chimeras to study receptor desensitization. Proc Natl Acad Sci U S A. 2000;97 (7) :3562-3566.|[2]Graham A. R. Johnston, et al. Neurologically-active compounds. WO1998058939A1|[3]Johnston GA. GABAc receptors: relatively simple transmitter -gated ion channels?. Trends Pharmacol Sci. 1996;17 (9) :319-323.